Skip to main content
Premium Trial:

Request an Annual Quote

Paradigm, Forma Therapeutics Partner to ID Molecular Markers for Preclinical Candidates

NEW YORK (GenomeWeb) – Paradigm and Forma Therapeutics today announced a multiyear partnership to identify predictive response biomarkers and measure pharmacodynamic activity for two of Forma's advanced preclinical candidates.

Paradigm will use its technology to evaluate the potential of molecular markers to predict clinical outcomes, which would enable Forma "to efficiently match our drugs with high-quality molecular assays to realize a personalized approach to cancer drug development," Forma President and CEO Steven Tregay said in a statement.

Through a spokesman, Forma declined to disclose the target and disease indications for the two therapeutic candidates. He added that certain details of the agreement are being finalized, but that for some projects Paradigm's PCDx test will be used, while for others, different assays could be developed.

PCDx is a next-generation sequencing-based cancer test that sequences both DNA and RNA.

Forma will also "be leveraging [Paradigm's] evidence team and biomarker expertise to develop target strategies," the spokesman said. Financial and other terms of the deal were not disclosed.

Last week Paradigm announced it initiated genomic testing for Pharmatech's AccessPPM Cancer Registry.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.